Reports: Ranbaxy ready for U.S. Aricept launch
Ranbaxy Laboratories has won FDA approval for its version of the Alzheimer's drug Aricept and plans to launch it in the U.S. market as early as today, media reports say, in a development that has analysts predicting at least $100 million in sales over the next six months. Report
Comments